Details for New Drug Application (NDA): 061901
✉ Email this page to a colleague
NDA 061901 describes KANTREX, which is a drug marketed by Apothecon and is included in six NDAs. Additional details are available on the KANTREX profile page.
The generic ingredient in KANTREX is kanamycin sulfate. There are five drug master file entries for this compound. Additional details are available on the kanamycin sulfate profile page.
The generic ingredient in KANTREX is kanamycin sulfate. There are five drug master file entries for this compound. Additional details are available on the kanamycin sulfate profile page.
Summary for 061901
| Tradename: | KANTREX |
| Applicant: | Apothecon |
| Ingredient: | kanamycin sulfate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 061901
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/2ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/3ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 75MG BASE/2ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
